TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00781066

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Controlled cord traction
Description: 1. Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn), hold it in one hand.~2. Place the other hand just above the woman's pubic bone and stabilize the uterus by applying counter-pressure during controlled cord traction.~3. Keep slight tension on the cord and await a strong uterine contraction (2-3 minutes).~4. With the strong uterine contraction, encourage the mother to push and very gently pull downward on the cord to deliver the placenta. Continue to apply counter-pressure to the uterus.~5. If the placenta does not descend during 30-40 seconds of CCT, do not continue to pull on the cord:~   * Gently hold the cord and wait until the uterus is well contracted again;~  * With the next contraction, repeat CCT with counter-pressure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: No controlled cord traction
Description: 1. Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn).~2. No CCT will be used and no fundal pressure. The placenta will be delivered physiologically, and signs for placental separation will be awaited (gush of blood from the vagina, descent of the umbilical cord, and increase in the height of the uterus in the abdomen as the lower segment was distended).~3. After separation, delivery of the placenta will be aided only by maternal expulsive efforts and/or gravity.
Study: NCT01370005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 high dose once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 low dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching BI 10773 high dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 10773 high dose
Study: NCT03285841

Intervention type: DEVICE
Intervention: OCT-AFI
Description: Both groups will be imaged with the OCT-AFI device. Imaging will not influence standard of care biospies, treatment and procedures.

Intervention type: DEVICE
Intervention: OCT-AFI
Description: Both groups will be imaged with the OCT-AFI device. Imaging will not influence standard of care biospies, treatment and procedures.
Study: NCT03808337

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy/SBRT
Description: Radiation to each metastatic site should be delivered to a minimum dose of 30 Gy in 5 fractions (BED of 48 Gy10). The exact dose of radiotherapy will be determined by the treating radiation oncologist. Preferred regimens for lung metastases include 50 Gy in five fractions, 48 Gy in four fractions, or 54 Gy in three fractions, although lower doses may be employed to respect dose limits to critical structures such as the esophagus. Recommended SBRT dosing for other sites includes 27 to 30 Gy in three fractions or 24 Gy in one fraction for bone metastases.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic Therapy/Standard of Care
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic Therapy/Standard of Care
Description: Standard of care systemic therapy, including chemotherapeutics, targeted therapies, immunomodulatory agents, and hormonal therapies will be delivered at the discretion of the treating oncologist. For patients randomized to receive SBRT, systemic therapy can be continued during SBRT at the discretion and concensus of treating physicians (medical oncologist and radiation oncologist). If the treating physicians recommend discontinuing systemic therapy during SBRT, general guidelines for stopping and reinitiating systemic regimen are as follows: Hormonal therapies and immunotherapy can be continued during SBRT. Consideration can be given to holding cytotoxic chemotherapy beginning 3 to 7 days prior to the initiation of SBRT until 3 to 7 days after the completion of SBRT. Similarly, consideration can be given to holding biologic agents during SBRT and for 0 to 3 days before and after.
Study: NCT05686772

Intervention type: DRUG
Intervention: Dopamine partial agonists
Description: Use of antipsychotics (i.e., dopamine partial agonists vs dopamine antagonists)

Intervention type: OTHER
Intervention: Psychiatric comorbidities
Description: Mainly substance use disorders and personality disorders

Intervention type: OTHER
Intervention: Sex
Description: Biological sex at birth

Intervention type: OTHER
Intervention: Gender
Description: Current gender identity

Intervention type: OTHER
Intervention: Socioeconomic status
Description: Including main source of income, employment status, homelessness

Intervention type: OTHER
Intervention: Gambling history
Description: History of gambling (i.e., recreational or problematic) prior to admission in the clinics
Study: NCT01743794

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: wound infusion, 0.2%, bolus 10mL followed by 8 mL/h infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution 0.9%
Description: wound infusion, 0.9%, bolus 10mL followed by 8 mL/h
Study: NCT02688465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine
Study: NCT03454464

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Conventional
Description: Conventional operation ,Thyroidectomy was performed first, and central compartment dissection was performed. This is a routine procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: central neck dissection first
Description: central neck dissection first ,after FNA confirmed of thyroid carcinoma, the central compartment neck dissection was carried out before thyroidectomy , finally complement of central compartment neck dissection.
Study: NCT02553811

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: accuracy diagnostic
Description: effectiveness of the ultrasonography and electromiography for best performance and diagnostic accuracy in carpal tunnel syndrome
Study: NCT02480816

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mineral water
Description: Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Mineral water
Description: Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
Study: NCT02630524

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: eHealth Behavioral Lifestyle Intervention Device: Telecoach
Description: Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eHealth Behavioral Lifestyle Intervention Device: Telecoach
Description: Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.
Study: NCT04636346

Intervention type: BEHAVIORAL
Intervention: Acceptance and Commitment Therapy
Description: Seven group sessions

Intervention type: OTHER
Intervention: Questionnaires
Description: Outcomes measured include anxiety, depression, fear of recurrence, psychological flexibility, mindfulness; values based living, and quality of life. Participants completed surveys at 4 time points, pre and post, and two follow-up time points.
Study: NCT00061113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoxetine + outpatient cognitive behavioral therapy
Description: single fixed morning dose 20 mg X 15 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluoxetine
Description: 20mg, QD x 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo + CBT
Description: single fixed morning dose X 16 weeks
Study: NCT04197011

Intervention type: DEVICE
Intervention: prosthetic device
Description: Individuals with TFA will use a combination of prosthetic devices.
Study: NCT03746184

Intervention type: OTHER
Intervention: Treatment course
Description: Pursued treatment for knee OA, including type of health care provider, time period of treatment course, and types of treatments received, will be recorded via the patient-reported questionnaire.
Study: NCT03915184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: zevor-cel
Description: A single autologous chimeric antigen receptor-B-cell maturation antigen (CAR-BCMA T cell) infusion
Study: NCT00189592

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArthroCare TOPAZ™ MicroDebrider™ using Coblation
Description: Percutaneous treatment of plantar fascia using the Topaz device. No incision performed.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Fasciotomy
Description: Standard surgical fasciotomy using an incision to treat the plantar fascia.
Study: NCT03183713

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Psychologically symptomatic patients will then be randomized to 4-8 weeks of placebo phone calls (Group PS-PL-Sx) or 4-8 weeks of cognitive behavior therapy treatment (PS-CBT-Sx) based on a 1:1 randomization ratio. Subjects randomized to receive CBT before surgery will proceed to 6 sessions given within 4-8 weeks by a licensed psychologist specializing in pain. CBT sessions will be 30 minutes in length, and focus on empirically supported behavior management, problem solving, cognitive restructuring, and relaxation training. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: Psychologically symptomatic patients will then be randomized to 4-8 weeks of placebo phone calls (Group PS-PL-Sx) or 4-8 weeks of cognitive behavior therapy treatment (PS-CBT-Sx) based on a 1:1 randomization ratio. Subjects randomized to receive CBT before surgery will proceed to 6 sessions given within 4-8 weeks by a licensed psychologist specializing in pain. CBT sessions will be 30 minutes in length, and focus on empirically supported behavior management, problem solving, cognitive restructuring, and relaxation training. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone.
Study: NCT02322814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
Study: NCT03183713

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sham Therapy
Description: Study nurse will conduct six sessions (30 minutes/ session) over a 4-8 week time period. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone. Sham sessions will entail how to prepare for surgery and expectations for recovery, and will go over content that the treatment and control groups will receive in handout form.
Study: NCT04443062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: PSMA radioligand therapy
Study: NCT02967289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: irinotecan (Campto®) 180 mg/m² on D1, IV infusion over 90 minutes to begin 30 min after folinic acid infusion is started
Study: NCT02322814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m\^2) by intravenous (IV) infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to cobimetinib will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered to Cohorts II and III at a dose of 840 mg IV every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 mg/m\^2 by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
Study: NCT00280657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valette
Description: 1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diane
Description: 1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
Study: NCT02034253

Intervention type: DRUG
Intervention: Risperidone
Description: Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.
Study: NCT03928002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4D Flow magnetic resonance imagery
Description: acquisition of anatomical, volume, right ventricular remodeling and intracardiac flow information

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac catheterization
Description: pulmonary vascular resistance calculation ;
Study: NCT03352843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine
Description: All patients will be administered with a single low-dose of primaquine in addition to standard artemether-lumefantrine regimen, and then followed-up for 28 days for clinical and laboratory assessment to assess safety and efficacy.
Study: NCT02484079

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polypectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Polypectomy
Study: NCT05341102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study: NCT01164228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Given PO
Study: NCT02440802

Intervention type: GENETIC
Intervention: Saliva sample collection for genetic analyses
Description: Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.
Study: NCT02390856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventus DRS
Description: The Conventus DRS (TM) is an intramedullary device intended to treat distal radius fractures. The device remains flexible during placement, but is made rigid at the completion of the surgical implant procedure. The implant is made from titanium alloy (Ti-6A1-4V) and Nitinol.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Volar Plate
Description: A volar plate is a metallic plate fastened directly to the fractured bone with screws, to hold the fracture fragments in proper position. Volar plate fixation is the traditional surgical method for distal radius fractures.
Study: NCT02565121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: corticosteroids

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: olfactory stimulation
Description: stimulation with odorants by sniffing 4 different odorants for a total of 5 minutes twice a day during 3 months
Study: NCT04263103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SJ-RS-WL2015 visual training program software
Description: It is a software with perceptual learning methods for binocular functions
Study: NCT00671905

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GP ablation
Description: HF stimulation-guided and anatomic ablation of the main right and left atrial GP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GP ablation
Description: HF stimulation-guided and anatomic ablation of the main right and left atrial GP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV isolation
Description: Circumferential PV isolation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PV isolation
Description: Circumferential PV isolation
Study: NCT02801188

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mixture of bupivacaine and dexmedetomidine
Description: Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye, and1 ug/kg of dexmedetomidine
Study: NCT02967289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfox Protocol
Description: every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: oxaliplatin (Eloxatin®) 85 mg/m² on D1, IV infusion over 2 hours, followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours 5-FU 2400 mg/m²/h IV continuous infusion over 46 hours starting at the end of folinic acid infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folfox Protocol
Description: every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: oxaliplatin (Eloxatin®) 85 mg/m² on D1, IV infusion over 2 hours, followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours 5-FU 2400 mg/m²/h IV continuous infusion over 46 hours starting at the end of folinic acid infusion
Study: NCT02837562

Intervention type: OTHER
Intervention: Slit lamp eye examination
Description: All participants in the trial will undergo a slit lamp eye examination

Intervention type: OTHER
Intervention: Slit lamp eye examination
Description: All participants in the trial will undergo a slit lamp eye examination
Study: NCT04644640

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telerehabilitation Therapy
Description: Rehabilitation services will be dispensed at patients' home utilizing video telecommunication services with real-time synchronous exchange of information - range of motion exercises for the knee, proprioception and balance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person Rehabilitation Therapy
Description: Range of motion exercises for the knee, proprioception and balance training
Study: NCT02938923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone
Description: Topical testosterone gel 1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Inactive skin gel

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supervised exercise training
Description: Multicomponent exercise program focused primarily on progressive resistance exercise training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Description: Multicomponent exercise program focused primarily on progressive resistance exercise training

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home exercise program
Description: Flexibility exercises performed at home 3 times per week and reviewed by study staff once a month.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education Modules
Description: 30-40 minute presentations conducted by study staff for participants focused on health concerns unrelated to exercise.
Study: NCT03454425

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exablate Subthalamotomy
Description: ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Exablate Subthalamotomy
Description: Sham ExAblate Subthalomotomy for the Treatment of Parkinson's Disease Motor Features